Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > Bloom Burton analyst David Martin PhD
View:
Post by wofats on Aug 17, 2024 10:58am

Bloom Burton analyst David Martin PhD

Bloom Burton analyst David Martin PhD has maintained their bullish stance on KHTRF stock, giving a Buy rating on August 9.

David Martin PhD has given his Buy rating due to a combination of factors that highlight the robust financial health and promising business trajectory of Knight Therapeutics. The company has demonstrated impressive year-over-year revenue growth, particularly in its key promoted products, which saw a significant increase. This growth indicates a strong market presence and effective sales strategies, outperforming both Bloom Burton’s and consensus estimates. The positive financial results suggest that Knight Therapeutics is on a path of sustained growth, making it a favorable investment opportunity.
Additionally, despite facing declines in sales of mature innovative and branded generic products, the overall financial performance of Knight Therapeutics remains solid. The company’s ability to offset these declines and still achieve a net revenue increase showcases its resilience and adaptability in a competitive pharmaceutical market. David Martin’s recommendation reflects confidence in Knight Therapeutics’ strategic direction, underlying strength of its core products, and its potential for continued success, justifying the Buy rating for its stock.

 
Comment by gudisgood on Aug 19, 2024 3:43am
Yes, Knight has been growing at a nice rate even through the time they haven't really launched new products and mainly just built their pipeline, and simultaneously had products come to the end of their cycles. Now we're about to enter a new phase... the first time the company launches products they've themselves sourced on a constant, frequent basis. With that said, the MOH contracts ...more  
Comment by GoldenInvestor on Aug 19, 2024 11:15am
& at the same time as the new products  get launched and generate increased revenues , the team keeps sourcing and making new relationships we don't even see yet. so much more to come!  So much geographic opportunity! So many health opportunities to tackle & cobtribute to!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities